SG/PUT/NOVO-NORDISK B/900/0.1/20.12.24 Stock

SG/PUT/NOVO-NORDISK B/900/0.1/20.12.24 Share Price

DE000SU7XCZ3

Market Closed - Bid/Ask 11:35:30 03/07/2024 pm IST			After market 12:11:53 am
0.84 ^EUR	+16.67%		0.86	+2.38%

Current month	+4.35%
1 month	-32.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/PUT/NOVO-NORDISK B/900/0.1/20.12.24

Latest news about NOVO NORDISK A/S

Sector Update: Health Care Stocks Fall in Afternoon Trading	10:22pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	09:38pm	MT
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says	09:29pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	09:21pm	MT

More news

Quotes 5-day view

Date	Price	Change
03/24/03	0.84	+16.67%
02/24/02	0.72	+12.50%
01/24/01	0.64	-7.25%
28/24/28	0.69	+1.47%
27/24/27	0.68	+1.49%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 11:35 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SU7XCZ
ISIN	DE000SU7XCZ3
Date issued	06/02/2024
Strike	900 kr
Maturity	20/12/2024 (170 Days)
Parity	10 : 1
Emission price	2.25 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	2.07 €
Lowest since issue	0.57 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	15.43x
Moneyness	0.9302
Difference Strike	-67.5 kr
Difference Strike %	-7.50%
Spread	0.04 €
Spread %	4.65%
Intrinsic value	0.000000
Present value	0.8600

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company